ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk Factors for Carbapenem-resistant Acinetobacter Baumannii

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00462579
Recruitment Status : Completed
First Posted : April 19, 2007
Last Update Posted : June 12, 2018
Sponsor:
Information provided by (Responsible Party):
University of Pittsburgh

Brief Summary:
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use [4], may be transmitted from person to person [5], and may be passed via environmental contamination [6]. Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms. The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.

Condition or disease
Acinetobacter Infections

Detailed Description:
The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.he following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.

Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
Actual Study Start Date : April 2007
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017



Primary Outcome Measures :
  1. dead or alive [ Time Frame: end of study ]
    health status



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
carbapenem-resistant acinetobacter baumannii positive cultures
Criteria

Inclusion Criteria:

  • Positive cultures of carbapenem-resistant acinetobacter baumannii

Exclusion Criteria:

  • Not meeting inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00462579


Locations
United States, Pennsylvania
UPMC
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: David L Paterson, MD University of Pittsburgh

Responsible Party: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00462579     History of Changes
Other Study ID Numbers: PRO07040057
First Posted: April 19, 2007    Key Record Dates
Last Update Posted: June 12, 2018
Last Verified: June 2018

Keywords provided by University of Pittsburgh:
carbapenem-resistant acinetobacter baumannii
positive culture
positive culture for carbapenem-resistant acinetobacter

Additional relevant MeSH terms:
Acinetobacter Infections
Moraxellaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections